RiboX wins FDA clearance for first circular RNA CAR therapy
August 10, 2026 | 11:08
RiboX Therapeutics received FDA IND clearance for RXIM002, the first circular RNA-based in vivo CAR therapy for autoimmune cytopenias, supporting the initiation of its Phase 1 clinical trial.
Mobile Version